Tags : CITYSCAPE

Roche to Present Results of Tiragolumab in P-II CITYSCAPE Study

Shots::stohShots: The P-II CITYSCAPE study involves assessing of tiragolumab+ Tecentriq (atezolizumab) vs Tecentriq + PBO to in 135 patients with 1L PD-L1-positive NSCLC. The full results of the study will be presented at ASCO20 Virtual Scientific Program The P-II study results: met its co-1EPs in IIT population, ORR (31.3% vs16.2%), mPFS (5.4 vs 3.6mos.), @exploratory […]Read More